Phase 1 Multiple Sclerosis Clinical Trials
47 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 47 trials
Recruiting
Phase 1Phase 2
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)250 enrolled1 locationNCT03109288
Recruiting
Phase 1
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Myasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead Company52 enrolled4 locationsNCT07304154
Recruiting
Phase 1
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
Multiple SclerosisProgressive Multifocal LeukoencephalopathyOther Neuroinflammatory Diseases With BBB Leakage
National Institute of Neurological Disorders and Stroke (NINDS)15 enrolled1 locationNCT05849467
Recruiting
Phase 1
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
Chronic Fatigue SyndromeHealthyMultiple Sclerosis+1 more
University of Alabama at Birmingham120 enrolled1 locationNCT03759522
Recruiting
Phase 1Phase 2
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals28 enrolled18 locationsNCT06617793
Recruiting
Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
Multiple Sclerosis
Hoffmann-La Roche129 enrolled32 locationsNCT05704361
Recruiting
Phase 1
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Multiple Sclerosis
AstraZeneca24 enrolled19 locationsNCT07224373
Recruiting
Phase 1
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 1Phase 2
MB-CART2019.1 in Refractory Multiple Sclerosis
Multiple SclerosisCAR-T Cell Therapy
Miltenyi Biomedicine GmbH26 enrolled1 locationNCT07178431
Recruiting
Phase 1
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Neuromyelitis Optica Spectrum Disorder (NMOSD)+6 more
Polina Stepensky120 enrolled1 locationNCT07085676
Recruiting
Phase 1
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
Progressive Multiple Sclerosis
Autolus Limited18 enrolled7 locationsNCT07139743
Recruiting
Phase 1Phase 2
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Multiple SclerosisMultiple Sclerosis (MS) Primary ProgressiveMultiple Sclerosis (MS) Secondary Progressive+2 more
Tr1X, Inc.39 enrolled2 locationsNCT07477639
Recruiting
Phase 1Phase 2
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Multiple Sclerosis (MS)Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Primary Progressive+4 more
University of California, San Francisco74 enrolled1 locationNCT05359653
Recruiting
Phase 1
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
Multiple SclerosisMultiple Sclerosis, Secondary ProgressiveMultiple Sclerosis, Primary Progressive
Stanford University12 enrolled1 locationNCT06138132
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Myasthenia GravisMultiple Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company120 enrolled35 locationsNCT06220201
Recruiting
Phase 1Phase 2
Molecular Imaging of NET Using [C-11]MRB-PET in MS
Multiple Sclerosis
Brigham and Women's Hospital19 enrolled1 locationNCT03207464
Recruiting
Phase 1Phase 2
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
Multiple SclerosisAlzheimer s Disease
Brigham and Women's Hospital250 enrolled1 locationNCT02649985
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
Multiple Sclerosis
Genentech, Inc.60 enrolled1 locationNCT07008378
Recruiting
Phase 1
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital12 enrolled1 locationNCT07361094